Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine

Eur Respir J. 2021 Jan 5;57(1):2003551. doi: 10.1183/13993003.03551-2020. Print 2021 Jan.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Acetylcysteine* / therapeutic use
  • Humans
  • Idiopathic Pulmonary Fibrosis* / drug therapy
  • Vital Capacity

Substances

  • Acetylcysteine